Koshida K, Yokoyama K, Imao T, Konaka H, Hirano K, Uchibayashi T, Namiki M
Department of Urology, School of Medicine, Kanazawa University, Japan.
Urol Res. 1998;26(1):23-8. doi: 10.1007/s002400050018.
To evaluate the ability of an anti-placental alkaline phosphatase (PLAP) monoclonal antibody (MAb) to localize to PLAP-expressing tumors, we established a model of testicular tumor with metastasis to lymph nodes and liver in severe combined immunodeficient (SCID) mice. 131I-labeled or 125I-labeled MAb was simultaneously administered via the intravenous or lymphatic route, respectively. Preferential accumulation of MAb in PLAP-expressing tumors at primary as well as metastatic sites was demonstrated. The percentage of the injected dose of MAb found in the tumor was generally higher when MAb was administered intravenously. Identical tumor/blood ratios were found with the two routes of administration. These data suggest that intravenous administration of a radiolabeled MAb is superior to lymphatic administration for tumor imaging and radioimmunotherapy.
为评估抗胎盘碱性磷酸酶（PLAP）单克隆抗体（MAb）定位到表达PLAP肿瘤的能力，我们在严重联合免疫缺陷（SCID）小鼠中建立了伴有淋巴结和肝脏转移的睾丸肿瘤模型。分别通过静脉或淋巴途径同时给予¹³¹I标记或¹²⁵I标记的MAb。结果表明，MAb在原发部位以及转移部位的表达PLAP的肿瘤中优先蓄积。静脉给予MAb时，在肿瘤中发现的注射剂量的百分比通常更高。两种给药途径的肿瘤/血液比率相同。这些数据表明，放射性标记的MAb静脉给药在肿瘤成像和放射免疫治疗方面优于淋巴给药。
